- Original Article
- Open Access
Urinary C-terminal telopeptide of type II collagen, radiological severity, and functional assessment in knee osteoarthritis: are these related?
Egyptian Rheumatology and Rehabilitation volume 43, pages 73–77 (2016)
Osteoarthritis (OA) is a chronic, debilitating joint disease characterized by the degeneration of articular cartilage, sclerosis of the subchondral bone, and osteophyte formation. This work aimed at estimating the level of urinary C-terminal telopeptide of type II collagen (CTX-II) as a biomarker of cartilage turnover and to determine its relation with radiological and functional assessment of knee OA.
Patients and methods
The current study included 40 postmenopausal women with symptomatic knee OA fulfilling the American Rheumatism Association clinical diagnostic criteria for knee OA. A total of 20 healthy volunteers were enrolled as a control group. Patients were assessed radiologically using the Kellgren–Lawrence grading system and functionally using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Urinary CTX-II was measured for the patient and control groups.
There was no statistically significant difference as regards age and BMI between patients and controls. Disease duration affects both function assessed using the WOMAC and cartilage degradation assessed using urinary CTX-II. There was a statistically significant correlation between the WOMAC and urinary CTX-II, whereas there was no statistically significant correlation between the Kellgren–Lawrence scale and both urinary CTX-II and the WOMAC.
This study further confirms that urinary CTX-II is an index of early cartilage degradation in knee OA even before radiological changes occurs. The functional assessment using the WOMAC is an easy inexpensive method in reflecting cartilage degradation. Moreover, this work supports the lack of association between the functional status of knee OA patients assessed using the WOMAC and their radiological severity measured using the Kellgren–Lawrence grading scale.
Alkan BM, Fidan F, Tosun A, Ardiçoğlu Ö. Quality of life and self-reported disability in patients with knee osteoarthritis. Mod Rheumatol 2014; 24:166– 171.
Duddy J, Kirwan JR, Szebenyi B, Clarke S, Granell R, Volkov S. A comparison of the semiflexed (MTP) view with the standing extended view (SEV) in the radiographic assessment of knee osteoarthritis in a busy routine X-ray department. J Rheumatol 2005; 44:349–351.
Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001; 60:619– 626.
Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002; 46:2613–2624.
Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001; 29:209–215.
Vignon E, Garnero P, Delmas P, Avouac B, Bettica P, Boers M, et al. Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers. Osteoarthritis Cartilage 2001; 9:289–293.
Poole AR. Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am 2003; 29:803–818.
Røtterud JH, Reinholt FP Beckstrøm KJ, Risberg M, Årøen A. Relationship between CTX-II and patient characteristics, patient-reported outcome, muscle strength, and rehabilitation in patients with a focal cartilage lesion of the knee: a prospective exploratory cohort study of 48 patients. BMC Musculoskeletal Disord 2014; 15:99.
Dahlbert L, Billinghurst C, Manner P, Ionescu M, Reiner A, Tanzer M, et al. Collagenase-mediated cleavage of type II collagen is selectively enhanced in osteoarthritis cartilage and can be arrested with a synthetic inhibitor which spares collagenase-1 (MMP-1). Arthritis Rheum 2000; 43:673–682.
Squires G, Ionescu M, Okouneff S, Poole AR. The pathobiology of focal lesions development in aging human articular cartilage and molecular matrix changes characteristic of osteoarthritis. Arthritis Rheum 2003; 48:1261–1270.
Poole AR. Cartilage in health and disease. In: Koopman W, editor Arthritis and allied conditions: a textbook of rheumatology. 14th ed Philadelphia: Lippincott, Williams & Wilkins; 2001. 226–284.
Atley LM, Sharma L, Clemens JD, Shaffer K, Pietka TA, Riggins JA, et al. The collagen II CTx degradation marker is generated by collagenase 3 and in urine reflects disease burden in knee OA patients. Trans Orthop Res Soc 2000; 25:168.
Guermazi M, Poiraudeau S, Yahia M, Mezganni M, Fermanian J, Habib Elleuch M, et al. Translation; adaptation, and validation of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for an Arab population: the Sfax modified WOMAC. Osteoarthr Cartil 2004; 12:259–268.
Escobar A, Quintana JM, Bilbao A, Aróstegui I, Lafuente I, Vidaurreta I. Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement. Osteoarthr Cartil 2007; 15:273–280.
Bellamy N. WOMAC osteoarthritis index: a user’s guide. London: University of Western Ontario; 1995.
Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000; 27:2635–2641.
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15:1833–1840.
Hmamouchi I, F Al, Tahiri L, Khazzani H, EL Mansouri L, Sanae A, et al. Clinically important improvement in the WOMAC and predictor factors for response to non-specific non-steroidal anti-inflammatory drugs in osteoarthritic patients: a prospective study. BMC Research Notes 2012; 5:58.
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29:1039–1049.
Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16:494–502.
Jansen NW, Roosendaal G, Lundin B, Heijnen L, Mauser-Bunschoten E, Bijlsma JW, et al. The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy. Arthritis Rheum 2009; 60:290–298.
Andersson ML, Petersson IF, Karlsson KE, Jonsson EN, Mansson B, Heinegard D, et al. Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis. Ann Rheum Dis 2006; 65:1490–1494.
Kong SY, Stabler TV, Criscione LG, Elliott AL, Jordan JM, Kraus VB, et al. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum 2006; 54:2496–2504.
Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predict cartilage loss over 21 months by MRI. Osteoarthritis Cartilage 2009; 17:384e389.
Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Uitterlinden AG, et al. A new marker for osteoarthritis-cross sectional and longitudinal approach. Arthitis Rheum Dis 2004; 50:2471–2478.
Karsdal MA, Byrjalsen AC, Bay Jensen AC, Henriksen K, Riis BJ, Christiansen C. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis — the effect of sex, Kellgren–Lawewnce (KL) score, body mass index (BMI), oral salmon calcitonin (SCT) treatment and diurnal variation. BMC Musculoskeletal disorders 2010; 11:125.
Ham KD, Loeser RF, Lindgren BR, Carlson SC. Effects of long term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum 2002; 46:1956–1964.
Cimen OB, Incel NA, Yapici Y, Apaydin D, Erdogan C. Obesity related measurements and joint space width in patients with knee osteoarthritis. J Med Sci 2004; 109:159–164.
Miller GD, Nicklas BJ, Loeser RF. Inflammatory biomarkers and physical function in older, obese adults with knee pain and self-reported osteoarthritis after intensive weight-loss therapy. J Am Geriatr Soc 2008; 56:644–651.
Darwish AF, Abdel-Ghany HS, El-Sherbini YM. Diagnostic and prognostic value of some biochemical markers in early knee osteoarthritis. Egypt Rheumatol 2012; 34:1–8.
Shereif WI, Hassanin AA. Comparison between uses of therapeutic exercise and heat application on relieve pain and improvement of physical function for patients with knee osteoarthritis. Life Sci J 2011; 8:388–396.
Rossignol M, Leclerc A, Allaert FA, Rozenberg S, Valat JP, Vouac BA, et al. Primary osteoarthritis of hip, knee, and hand in relation to occupational exposure. Occup Environ Med 2005; 62:772–777.
Cibere J, Zhang H, Garnero P, Poole AR, Lobanok T, Saxne T, et al. Association of association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population based study. Arthritis Rheum 2009; 60:1372–1380.
Cubukcu D, Sarsan A, Alkan H. Relationship between pain, function and radiographic findings in osteoarthritis of the knee: a cross-sectional study. Arthritis 2012; 1:5.
Hannan MT, Felson DT, Pincus T. Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J Rheumatol 2000; 27:1513–1517.
Falaffi F, Cavalieri F, Nolli M, Ferraccioli G. Analysis of disability in knee ostoarthritis. Relationship with age and psychological variables but not with radiographic score. J Rheumatol 1991; 18:1581–1586.
Külcü DG, Yanık B, Atalar H, Gülsen G. Associated factors with pain and disability in patients with knee osteoarthritis. Turk J Rheumatol 2010; 25:77–81.
Rupprecht TN, Oczipka F, Lüring C, Pennekamp PH, Grifka J. Is there a correlation between the clinical, radiological and intra-surgical findings of osteoarthritis of the knee? A prospective study on 103 patients. Z Orthop Unfall 2007; 145:430–435.
Felson TD, Naimark A, Anderson J. The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum 1987; 30:914–918.
McAlindon TE, Cooper C, Kirwan JR, Dieppe PA. Determinants of disability in osteoarthritis of the knee. Ann Rheuma Dis 1993; 52:258–262.
Lethbridge-Cejku M, Scott WJr, Reichle R, Ettinger WH, Zonderman A, Costa A. Association of radiographic features of osteoarthritis of the knee with knee pain: data from the Baltimore Longitudinal Study of Aging. Arthritis Care Res 1995; 8:182–188.
Cicuttini FM , Baker J, Hart DJ, Spector TD. Association of pain with radiological changes in different compartments and views of the knee joint. Osteoarthritis Cartilage 1996; 4:143–147.
Hodler J, Resnick D. Current status of imaging of articular cartilage. Skeletal Radiol 1996; 25:703–709.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
About this article
Cite this article
Abdel Ghany, H.M., El Tawab, S.S. & Moghazy, A.M. Urinary C-terminal telopeptide of type II collagen, radiological severity, and functional assessment in knee osteoarthritis: are these related?. Egypt Rheumatol Rehabil 43, 73–77 (2016). https://doi.org/10.4103/1110-161X.181879
- knee osteoarthritis
- urinary C-terminal telopeptide of type II collagen
- Western Ontario and McMaster Universities Osteoarthritis Index